



ASX & Media Release

Issue of Securities under Entitlement Offer

Melbourne, Australia; 5 August, 2020: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, advises that further to its ASX announcement dated 3 August 2020, it has now completed the issue and allotment of 357,530,827 fully paid ordinary shares (**Shares**) and a total of 126,677,087 Options. The Options issued comprise 119,177,087 free attaching options applied for under the fully underwritten non-renounceable Entitlement Offer (**Entitlement Offer**) raising \$4.29m (before costs), and 7,500,000 Options which have been issued to Lazarus Corporate Finance Pty Limited (**Underwriter and Lead Manager**), pursuant to the terms of the Underwriting Agreement set out in the Entitlement Offer Prospectus (**Prospectus**) lodged on 22 June 2020.

As a result of the issue of Shares under the Entitlement Offer there are now 1,430,121,152 Shares on issue. The Company is also pleased to advise that the 126,677,087 Options will be quoted on the terms and conditions as set out in the Prospectus announced on 22 June 2020.

The Appendix 2A's in relation to the issue of the abovementioned Shares and Options will follow.

A statement setting out the names and percentages of Options held by the 20 largest Option holders, and a distribution schedule for the Options, will be attached to the Appendix 2A relating to the Options.

-Ends-

This ASX release was authorised on behalf of the Patrys Board by:

James Campbell, Managing Director and CEO

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media enquiries:

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Registered Office Address

Level 4, 100 Albert Road
South Melbourne VIC 3205

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its Deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com.



About Patrys' Deoxymab 3E10 platform – lead candidates PAT-DX1 and PAT-DX1-NP:

Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in orthotopic models of both triple negative breast cancer brain metastases and glioblastoma. PAT-DX1 has also been shown to enhance the therapeutic effect of low dose radiation. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.